Navigation Links
PrimeraDx Appoints Leroy Hood to its Scientific Advisory Board
Date:12/6/2011

MANSFIELD, Mass., Dec. 6, 2011 /PRNewswire/ -- PrimeraDx today announced that Leroy Hood, MD, PhD, a world recognized leader in the molecular device industry, has been appointed to its Scientific Advisory Board. 

"High multiplex qPCR diagnostics is a key step in bringing personalized medicine to the clinic," commented Dr. Hood.  "I am delighted to help PrimeraDx take the step from an innovative next generation qPCR platform to a robust molecular diagnostics solution."

"Lee brings a breadth of knowledge in the molecular device industry that no one else has.  With Lee's scientific vision we will move forward with our goal of transforming molecular diagnostic medicine and improving patient care," said President and CEO Matthew McManus.

Dr. Hood has established a systems approach to understanding the complexity of biology and medicine.  He has played a pivotal role in the DNA sequencing industry and his innovations were essential for the sequencing of the human genome.  Dr. Hood has been instrumental in the founding of numerous research and commercial enterprises, including Applied Biosystems, Amgen and the Institute for System Biology, where he currently holds the position of President.  He has won several awards and accolades, including; the 2003 AMP award for excellence in Molecular Diagnostics, the Academy of Engineering's Russ Prize, the Lasker Award and the Kyoto Prize.  Dr. Hood has more than 700 peer reviewed articles and is a member of the National Academy of Sciences, the National Academy of Engineering and the Institute of Medicine.

About PrimeraDx

PrimeraDx is a molecular diagnostics company that has developed, and is commercializing, a novel, game-changing clinical platform which combines PCR with capillary electrophoresis.  The result of combining these two well-known technologies into a bench-top instrument is the ability to deliver highly multiplexed and quantitative answers to the clinic.  The company is pursuing a two pronged strategy to sell the system in an Open Platform Mode to clinical labs and to collaborate with pharmaceutical companies to develop high-value companion and enabling diagnostic products.  Users can easily design very complex multi-modal assays that test for disparate target types, like SNPs, expression biomarkers, microRNAs and fusion genes.  PrimeraDx's technology represents the next generation of quantitative PCR.  The Company is backed by a strong group of experienced venture-capital investors, including Abingworth, InterWest Partners, CHL Medical Partners, and Malaysia Technology Development Corporation.  The Company's website is: www.primeradx.com or www.multiplexpcr.com.

CONTACT: Andrew Bond, +1-508-618-2752, abond@primeradx.com


'/>"/>
SOURCE PrimeraDx
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PrimeraDx Appoints David Heffelfinger as VP of Engineering and Systems Development
2. PrimeraDx Launches the Only System Capable of Simultaneous Quantification of mRNA, microRNA and DNA
3. Ulthera Appoints Greg Waller as Chief Financial Officer
4. Tengion Appoints John L. Miclot President and Chief Executive Officer
5. Remedi SeniorCare® Appoints Corey Gauff SVP of Sales and Account Management
6. Ultragenyx Appoints Tom Kassberg as Chief Business Officer and Announces Management Team
7. CVS Caremark Appoints Kevin Murphy President of Accordant Business
8. Valeant Pharmaceuticals Appoints Howard B. Schiller as Chief Financial Officer
9. Adeona Appoints Jeff Lucero Riley as Independent Chairman
10. Champions Oncology, Inc. Appoints Executive Vice President and Chief Financial Officer to Management Team and Corporate Office Relocation
11. InterMune Appoints Angus C. Russell to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... Inc. ("Hill-Rom") (NYSE: HRC ) today ... ended March 31, 2017, and raised its outlook ... guidance reflect the contribution from the Mortara Instrument ... 14, 2017.  For the fiscal second ... share compared to $0.33 per diluted share in ...
(Date:4/26/2017)... Phoenix Marketing Solutions ( Phoenix ) ... mission of transforming science into clinical practice. During a time ... innovative approach supports the life sciences industry by ... in science and medicine — which ultimately improves lives. ... 2002 by Tracy Doyle and Angela Fiordilino ...
(Date:4/25/2017)... Endo International plc (NASDAQ: ENDP ) will announce its ... management team will host a conference call and webcast before the ... The dial-in number to access the call is U.S./ Canada ... 6086379. Please dial in 10 minutes prior to the scheduled start ... call will be available from May 9, 2017 at 11:30 a.m. ...
Breaking Medicine Technology:
(Date:4/28/2017)... Abilene, Texas (PRWEB) , ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... says, reveals which name the Creator responds to and which He does not. Yisrayl ... to believe which one is the true name, but he says with a little Scripture, ...
(Date:4/28/2017)... LAKE CITY, UTAH (PRWEB) , ... April 28, ... ... Côté as Account Manager for the North East region. Côté has 20+ years ... and consulting. Prior to Phytomer, Côté worked with an array of high-end cosmetic ...
(Date:4/28/2017)... New York (PRWEB) , ... April 28, 2017 ... ... anti-aging skincare and advanced nutraceutical supplements, through its Nova Skin Sciences ... provides the hydrating benefits of a moisturizer with the power of an anti-aging ...
(Date:4/28/2017)... ... ... Lowe is a popular actor that has been in many different movies and television ... host of the “Informed” series. The program focuses on many important issues that society ... thyroid cancer. , Although thyroid cancer is an uncommon type of cancer, people still ...
(Date:4/28/2017)... ... 28, 2017 , ... Christie Medical Holdings, Inc. , with its market-leading ... Braun Medical Inc. , a leader in infusion therapy and pain management. , ... 90 percent of hospital patients receiving a peripheral IV catheter as part of their ...
Breaking Medicine News(10 mins):